###### Key messages

-   Vitamin D did not protect against lupus activity.

-   Beta-carotene, fatty acid C18:2 and vitamin B6 may protect against increases in GC dose.

-   Higher GC dose levels indicated increased appetite.

Introduction {#s1}
============

Glucocorticoids (GCs) are very effective in treating inflammation, but long-term GC treatment is associated with several side effects.[@R1] [@R2] GC treatment may reflect disease activity in patients with systemic lupus erythematosus (SLE) with regard to GC treatment dose change over time and/or dose levels. Patients with higher disease activity might be more dependent on GCs than those with lower disease activity. In addition, higher GC doses may be seen in patients with higher disease activity.[@R3] [@R4]

Little is known regarding the dietary habits in SLE. A few studies have reported that patients with SLE might have a poor nutritional status compared with the general population, showing low consumption of fruits and vegetables as well as inadequate dietary intake of fibre, vitamin B~6~, calcium and polyunsaturated fatty acids, especially omega-3 fatty acids.[@R5] Elkan *et al*[@R8] have, in the present cohort, specifically found decreased dietary intake of polyunsaturated fatty acids (including omega-3 and omega-6) and fibre compared with healthy controls. Previous findings suggest that vitamin D and moderate alcohol intake are beneficial for patients with SLE. Vitamin D deficiency has been linked with higher disease activity in patients with SLE[@R9] and moderate alcohol consumption has shown to be associated with reduced risk of SLE.[@R13] However, there is a lack of studies on the link between diet and treatment results in SLE. Since GCs are frequently used to control active SLE, our interest was to focus on the association between diet and GC treatment. The aim of this study was to investigate whether diet influences GC treatment in patients with SLE.

Methods {#s2}
=======

Study participants {#s2a}
------------------

This study included patients with SLE, fulfilling the 1982 revised criteria of the American College of Rheumatology (ACR) for SLE, from the SLE Vascular Impact Cohort (SLEVIC), Karolinska University Hospital, Stockholm, Sweden. Recruitment and inclusion for SLEVIC have been previously described in detail by Anania *et al*.[@R16] The inclusion criterion was all patients who completed Food Frequency Questionnaire (FFQ) at inclusion.

Dietary assessment {#s2b}
------------------

Patients were asked to complete a semiquantitative FFQ at inclusion. This self-reported FFQ involved frequency of intake of 88 food items and beverages during the previous year from inclusion. Completed FFQs were evaluated and an estimation of daily mean intake of 49 nutrients was calculated, using nutrient composition values based on the Swedish National Food Administration data.

GC treatment {#s2c}
------------

Data on GC use and dose levels were extracted from medical records at three time points; at inclusion and at 1 year before and after inclusion. Based on GC use at the three time points, GC dose changes over time, reflecting disease activity, were adjusted for three time periods: previous year to inclusion, following year from inclusion and 1 year before to 1 year after inclusion. GC use over time was categorised into four treatment status groups: 'none', 'discontinued', 'started' and 'continued'. Dose changes over time were categorised into 'decreased', 'unchanged' and 'increased'. GC treatment and higher dose levels (\>5.0 mg/day and \>7.5 mg/day) were considered a proxy for more active SLE; unchanged or increased GC doses were considered as unfavourable outcomes.

Statistical analysis {#s2d}
--------------------

Statistical analysis was performed with IBM SPSS Statistics V.22. We linked dietary data from FFQ with data on GC treatment from medical records for the year preceding and the year following the FFQ. Associations between diet and GC treatment during the 2-year period were analysed with logistic regression adjusted for age and gender. All nutrient variables were dichotomised into lower and higher intakes with a cut-off at median levels.

Results {#s3}
=======

This study included 111 patients with SLE. Patient characteristics are presented in [table 1](#LUPUS2015000135TB1){ref-type="table"}.

###### 

Patient characteristics at inclusion

  Patient characteristics     N=111
  --------------------------- -----------
  Age (years), mean±SD        48.0±13.2
  Female, n (%)               98 (88.3)
  BMI (kg/m^2^), mean±SD      24.9±4.5
  Current smokers, n (%)      15 (13.5)
  CRP (mg/L), mean±SD         4.6±6.6
  ESR (mm), mean±SD           23.2±17.3
  Glucose (mmol/L), mean±SD   4.6±0.9
  SLAM, median (IQR)          6 (4--9)
  SLEDAI, median (IQR)        2 (0--6)
  SLICC-DI, median (IQR)      1 (0--3)

BMI, body mass index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; SLAM, systemic lupus activity measure; SLEDAI, systemic lupus erythematosus disease activity index; SLICC-DI, systemic lupus international collaboration clinics damage index.

During the 2-year period, the percentage of patients treated with GC ranged between 56.8% and 59.5%. In addition to GC, the most common treatments were hydroxychloroquine (HCQ) and azathioprine (AZA); the percentages of patients treated with HCQ and AZA ranged between 40.5--46.8% and 18.9--25.2%, respectively ([table 2](#LUPUS2015000135TB2){ref-type="table"}). Almost all the patients who were treated with GC at inclusion took also supplementation of calcium+vitamin D (66.7%) or calcium (24.2%) or vitamin D (6.1%) alone.

###### 

Overview of treatment use and doses at −1 year, inclusion and +1 year

             −1 year     Inclusion      +1 year                                
  ---------- ----------- -------------- ----------- -------------- ----------- --------------
  GC         63 (56.8)   5.9±2.5        66 (59.5)   6.3±3.9        64 (57.7)   7.7±7.8
  HCQ        46 (41.4)   251.0±91.2     52 (46.8)   232.9±81.1     45 (40.5)   247.2±86.4
  AZA        28 (25.2)   115.4±41.2     21 (18.9)   104.0±40.1     23 (20.7)   103.3±33.1
  MTX        8 (7.2)     13.1±6.6       9 (8.1)     15.3±4.8       7 (6.3)     14.7±6.2
  MMF        8 (7.2)     1406.3±581.5   8 (7.2)     1068.8±628.5   6 (5.4)     1041.7±510.3
  CyA        6 (5.4)     159.2±34.7     6 (5.4)     176.7±97.3     6 (5.4)     133.3±40.8
  CYC        0 (0)       --             1 (0.9)     700\*          0 (0)       --
  GC pulse   0 (0)       --             0 (0)       --             0 (0)       --

\*mg/month during 6 months.

AZA, azathioprine; CyA, cyclosporin A; CYC, cyclophosphamide; GC, glucocorticoid; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; MTX, methotrexate.

During the 2-year period, 26 patients (23.4%) did not use GC, 4.5% discontinued their GC treatment, 5.4% started GC treatment and 48.6% had continuous GC treatment. 20 patients (18%) had missing data. The distribution of GC treatment statuses over the three time periods is presented in [figure 1](#LUPUS2015000135F1){ref-type="fig"}.

![Treatment status of glucocorticoid (GC) from −1 year to inclusion, inclusion to +1 year and --1 year to +1 year.](lupus2015000135f01){#LUPUS2015000135F1}

Of the 54 patients who had continued treatment over the 2-year period, 31.5% had decreased dose, 35.2% had unchanged dose and 33.3% had increased dose. GC dose changes during the three time periods are presented in [table 3](#LUPUS2015000135TB3){ref-type="table"}.

###### 

GC dose change (decreased/unchanged/increased) from --1 year to inclusion, inclusion to +1 year and --1 year to +1 year

              −1 year to Inclusion (n=58)   Inclusion to +1 year (n=60)   −1 year to +1 year (n=54)                             
  ----------- ----------------------------- ----------------------------- --------------------------- ------------- ----------- -------------
  Decreased   20 (34.5)                     −3.12±1.30                    14 (23.3)                   −4.51±4.63    17 (31.5)   −2.76±1.9
  Unchanged   24 (41.4)                     --                            25 (41.7)                   --            19 (35.2)   --
  Increased   14 (24.1)                     +4.76±2.91                    21 (35.0)                   +6.65±12.41   18 (33.3)   +7.64±12.45

GC, glucocorticoid.

The association between dietary nutrient intake and GC use is presented in [table 4](#LUPUS2015000135TB4){ref-type="table"}. Vitamin D was associated with GC treatment (OR 2.70--2.85, (95% CI 1.00 to 8.11)), whereas alcohol was inversely associated with GC treatment (OR 0.28--0.39, (95% CI 0.10 to 98)).

###### 

The association between dietary nutrient intake and GC use between −1 year to inclusion, inclusion to +1 year and −1 year to +1 year

  Time period            Nutrient\*    OR†            95% CI         p Value
  ---------------------- ------------- -------------- -------------- ---------
  −1 year to Inclusion   Alcohol (g)   0.39           0.16 to 0.98   0.045
  Inclusion to +1 year   Alcohol (g)   0.31           0.12 to 0.79   0.015
  Vitamin D (µg)‡        2.70          1.01 to 7.18   0.046          
  −1 year to +1 year     Alcohol (g)   0.28           0.10 to 0.79   0.016
  Vitamin D (µg)‡        2.85          1.00 to 8.11   0.050          

\*All nutrients are dichotomised into lower (\<median) intake and higher (\>median) intake. Low intake=referent group.

†OR adjusted for age and gender.

‡Not significant after adjusting for calcium/vitamin D supplementation.

GC, glucocorticoid.

The association between dietary nutrient intake and unchanged/increased GC dose is presented in [table 5](#LUPUS2015000135TB5){ref-type="table"}. Beta-carotene, fatty acid C18:2 and vitamin B~6~ were inversely associated with unchanged/increased GC dose (OR 0.29--0.30 (95% CI 0.10 to 0.90)), whereas vitamin B~12~ and calcium were associated with unchanged/increased GC dose (OR 3.20--5.36 (95% CI 1.08 to 17.52)). Omega-3 fatty acids and the ratio between omega-6 and omega-3 fatty acids were not significantly associated with unchanged/increased GC dose.

###### 

The association between dietary nutrient intake and GC dose change (decreased vs unchanged/increased) between --1 year to inclusion, inclusion to +1 year and −1 year to +1 year

  Time period            Nutrient\*             OR†    95% CI          p Value
  ---------------------- ---------------------- ------ --------------- ---------
  −1 year to Inclusion   Beta-carotene (µg)     0.29   0.10 to 0.88    0.029
  Inclusion to +1 year   Vitamin B~12~ (µg)     3.72   1.08 to 12.84   0.038
  −1 year to +1 year     Fatty acid C18:2 (g)   0.30   0.10 to 0.90    0.031
                         Vitamin B~6~ (µg)      0.29   0.10 to 0.87    0.027
                         Calcium (mg)‡          5.36   1.64 to 17.52   0.005
                         Vitamin B~12~ (µg)     3.20   1.08 to 9.43    0.035

\*All nutrients are dichotomised into lower (\<median) intake and higher (\>median) intake. Low intake=referent group.

†OR adjusted for age and gender.

‡After adjusting for calcium/vitamin D supplementation: OR=5.60 (95% CI 1.67 to 18.76).

GC, glucocorticoid.

Total energy intake was associated with GC doses \>5.0 mg/day and \>7.5 mg/day, explaining an association between 35 nutrients and higher GC dose levels (OR 2.98--23.82 (95% CI 1.01 to 203.88)).

Discussion {#s4}
==========

This study focused on the association between diet and GC treatment in patients with SLE. The results were based on data from a Swedish SLE cohort and showed that some dietary nutrients were associated or inversely associated with unfavourable outcomes of GC.

Diet and GC treatment {#s4a}
---------------------

Several previous studies have shown that low vitamin D levels in serum are associated with disease activity in SLE.[@R12] [@R17] Vitamin D supplementation has also been suggested to improve disease activity and fatigue scores in SLE.[@R21] [@R22] Based on these and other studies, it has been suggested that vitamin D is protective against lupus activity. However, in this study, dietary vitamin D was positively associated with GC treatment, not suggesting a protective effect, but this association was not significant after adjusting for supplement use of calcium/vitamin D supplementation. Patients included in this study might have been aware of the existing evidence of the beneficial effect of vitamin D, explaining an increased vitamin D intake in patients with GC treatment/higher disease activity. Nevertheless, these results were based on dietary intake and not supplement intake of vitamin D. The results on the association between dietary vitamin D and GC were affected by calcium/vitamin D supplementation. However, if an adequate vitamin D intake is obtained (either through diet or supplementation), it is not necessarily followed by adequate vitamin D levels in blood, since GC reduces absorption of vitamin D.[@R23]

Alcohol was inversely associated with GC treatment, reflecting older findings on the link between moderate alcohol intake and reduced risk of rheumatic diseases,[@R24] [@R25] and even specifically of SLE.[@R13]

Diet and unchanged/increased GC dose {#s4b}
------------------------------------

Fatty acid C18:2 (linoleic acid) was inversely associated with unchanged/increased GC dose (unfavourable outcome). Fatty acid C18:2 belongs to the omega-6 family and is known to have proinflammatory properties. However, the omega-3 fatty acids (anti-inflammatory) should be considered when looking at the omega-6 intake since the ratio between these two must be well balanced. The omega-6 to omega-3 fatty acid ratio did not show any association with unchanged/increased GC dose. Though, a review has gathered evidence on health benefits of conjugated linoleic acids[@R26] that may be linked with the inverse association between dietary linoleic acid and unchanged/increased GC dose.

An inverse association was found between beta-carotene and unchanged/increased GC dose. Beta-carotene is an antioxidant and patients with SLE have been found to have lower dietary beta-carotene intake compared with controls.[@R27] Increased antioxidant intake could be beneficial due to the damage of free oxygen radicals that play a role in SLE.[@R28] [@R29] Beta-carotene may be linked to protective effect against unchanged/increased GC dose.

Vitamin B~6~ was inversely associated with unchanged/increased GC dose. Higher intake of vitamin B~6~ and dietary fibre may prevent the occurrence of active disease in patients with SLE.[@R6] Pyridoxal 5′-phosphate (PLP) is the active coenzyme form of vitamin B~6~ and its concentration in plasma is the most common measure of vitamin B~6~ status.[@R30] [@R31] Decreased plasma PLP levels have shown to be associated with chronic or acute disease and increased plasma PLP levels with lower C reactive protein.[@R32] Increased dietary vitamin B~6~ intake may play a role in lupus activity.

Diet and GC dose {#s4c}
----------------

Energy intake was associated with higher GC dose levels, explaining the association between almost all the nutrients and higher GC dose levels. Contradictory results exist on the effects of GC therapy on energy intake, appetite and body weight in humans.[@R35] GC has shown to be associated with increased appetite and/or body weight.[@R36] Increased appetite during or after GC treatment has been self-reported as one of the major adverse events in several studies.[@R37] This study confirms the existing evidence of GC\'s influence on increasing appetite.

Limitations {#s4d}
-----------

Patients included in this study had various disease and treatment durations at inclusion. GC treatment may not have fully reflected lupus activity during the 2-year period. Some micronutrients, when consumed together, interfere with each other in the physiological environment; however, interactions between nutrients as well as nutrient bioavailability were not taken into account. Dietary data from FFQ were based on estimated dietary consumption. Recall bias and under-reporting and over-reporting may have occurred when completing the FFQ. Also, dietary patterns were assumed to be the same throughout the 2-year period. Clinical manifestations, treatment history and side effects of GC throughout the disease course from diagnosis were not considered in this study.

Conclusions {#s5}
===========

These data did not support the hypothesis that dietary vitamin D protects against lupus activity. Beta-carotene (antioxidant), fatty acid C18:2 (omega-6) and vitamin B~6~ may protect against unfavourable outcomes (need for increases in GC dose). The inverse association between alcohol intake and GC treatment/lupus activity may provide a partial explanation for the link between moderate alcohol intake and improved cardiovascular health in rheumatic diseases. The association between dietary intake and higher GC dose levels indicated GC\'s influence on increasing appetite.
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